While combinatory therapies with FLT3 inhibitors and standard chemotherapy are routinely used to treat FLT3 ITD-positive AML patients in particular, combinatory multi-target kinase inhibition awaits approval. This evidence concerns the gene FLT3 and acute myeloid leukemia.